A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease-modifying antirheumatic drugs with active psoriatic arthritis

Author(s):
Mease, P.J.; Heijde, D. van der; Ritchlin, C.T.; Cuchacovich, R.S.; Shuler, C.L.; Lin, C.; Vangerow, H.; Samanta, S.; Lee, C.H.; Gladman, D.D.
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-03-31
Language
English
Is part of
Experimental Dermatology (2017), Vol. 26, no. 3, p. E30-E30
hdl
1887/114603